Renuvion Safely and Effectively Treats Lax Skin in Trial
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
Plastic surgeon Paul S. Kim, MD, discusses his role in the Renewing Lives campaign and how minimally invasive skin-tightening treatments like Renuvion are helping patients address post-weight loss skin laxity.
Phase 4 study data presented at the American Academy of Pain Medicine PainConnect 2026 meeting reported that more than 90% of patients undergoing aesthetic or reconstructive procedures remained opioid-free when treated with Journavx as part of multimodal pain therapy.